Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

Launched by IPSEN · Jul 12, 2018

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Premenopausal women aged 25-40 years old
• • With symptomatic internal genital endometriosis - at least mild menorrhagia present or worse
• • Internal genital endometriosis diagnosis is based on enlarged uterus detected by pelvic bimanual examination and ultrasound examination (stages I-II-III by Demidov in accordance with ultrasound results not earlier than 2 months before first injection
• • Naive patients who have never been prescribed a GnRH agonist
• Exclusion Criteria:
• • Pregnant subjects
• • Subjects with hypersensitivity to GnRH analogue or to one of its excipients
• • Subjects treated with any other investigational drug within the last 30 days before study entry
• • Subjects' refusal to participate in the study